KR20240021188A - 체크포인트 키나제 1(chk1) 억제제 및 그의 용도 - Google Patents

체크포인트 키나제 1(chk1) 억제제 및 그의 용도 Download PDF

Info

Publication number
KR20240021188A
KR20240021188A KR1020237044236A KR20237044236A KR20240021188A KR 20240021188 A KR20240021188 A KR 20240021188A KR 1020237044236 A KR1020237044236 A KR 1020237044236A KR 20237044236 A KR20237044236 A KR 20237044236A KR 20240021188 A KR20240021188 A KR 20240021188A
Authority
KR
South Korea
Prior art keywords
alkyl
pharmaceutically acceptable
tautomer
stereoisomer
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237044236A
Other languages
English (en)
Korean (ko)
Inventor
앤서니 비 핑커톤
스티븐 토드 메이어
쟈크 모거
옌 팜 홍 트루옹
레이첼 자넷 엘스돈
Original Assignee
바운드리스 바이오, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바운드리스 바이오, 인크. filed Critical 바운드리스 바이오, 인크.
Publication of KR20240021188A publication Critical patent/KR20240021188A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237044236A 2021-05-27 2022-05-26 체크포인트 키나제 1(chk1) 억제제 및 그의 용도 Pending KR20240021188A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163193990P 2021-05-27 2021-05-27
US63/193,990 2021-05-27
PCT/US2022/031141 WO2022251502A1 (en) 2021-05-27 2022-05-26 Checkpoint kinase 1 (chk1) inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
KR20240021188A true KR20240021188A (ko) 2024-02-16

Family

ID=84229213

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237044236A Pending KR20240021188A (ko) 2021-05-27 2022-05-26 체크포인트 키나제 1(chk1) 억제제 및 그의 용도

Country Status (12)

Country Link
US (2) US11707462B2 (cg-RX-API-DMAC7.html)
EP (1) EP4347582A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024520481A (cg-RX-API-DMAC7.html)
KR (1) KR20240021188A (cg-RX-API-DMAC7.html)
CN (1) CN117715905A (cg-RX-API-DMAC7.html)
AU (1) AU2022282384A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024571A2 (cg-RX-API-DMAC7.html)
CA (1) CA3219348A1 (cg-RX-API-DMAC7.html)
IL (1) IL308759A (cg-RX-API-DMAC7.html)
MX (1) MX2023014028A (cg-RX-API-DMAC7.html)
TW (1) TW202313588A (cg-RX-API-DMAC7.html)
WO (1) WO2022251502A1 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023002453A2 (pt) 2020-08-12 2023-05-02 Boundless Bio Inc Composições de agente de via de estresse de replicação e métodos para tratar câncer
MX2023006364A (es) * 2020-11-30 2023-06-13 Sumitomo Pharma Co Ltd Derivado de 5-heteroaril-1h-pirazol-3-amina.
EP4347582A4 (en) 2021-05-27 2025-05-07 Boundless Bio, Inc. CHECKPOINT KINASE-1 INHIBITORS AND USES THEREOF
CA3241992A1 (en) * 2021-12-24 2023-06-29 Seiji Kamioka 1h-pyrazole-3-amine derivative having bicyclic backbone
CN119546588A (zh) * 2022-05-24 2025-02-28 无界生物公司 吡啶检查点激酶1(chk1)抑制剂及其用途
CN119255990A (zh) * 2022-05-25 2025-01-03 曙方医药 作为检查点激酶1抑制剂的含氮五元杂环衍生物及其用途
EP4626433A1 (en) * 2022-11-29 2025-10-08 Boundless Bio, Inc. Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof
TW202440549A (zh) * 2022-11-29 2024-10-16 美商無界生物公司 檢查點激酶1(chk1)抑制劑及其用途
EP4683635A1 (en) * 2023-03-20 2026-01-28 Boundless Bio, Inc. Uses of a checkpoint kinase 1 (chk1) inhibitor
JP2026513823A (ja) * 2023-04-03 2026-05-01 バウンドレス バイオ,インク. チェックポイントキナーゼ1(chk1)阻害剤の結晶形態およびその使用
US20260232659A1 (en) * 2023-04-03 2026-08-13 Boundless Bio, Inc. Checkpoint kinase 1 (chk1) inhibitor pharmaceutical composition
EP4753712A1 (en) * 2023-08-02 2026-06-10 Health Research, Inc. Sequential treatment method for p53-deficient cancer
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026108769A1 (en) 2024-11-19 2026-05-28 Groovy Medicine (Hangzhou) Ltd. Substituted 2- [ (5-cyanopyrazin-2-yl) amino] pyridines, their prodrugs and uses thereof
WO2026108771A2 (en) 2024-11-19 2026-05-28 Groovy Medicine (Hangzhou) Ltd. Substituted heteroaromatic compounds as inhibitors of checkpoint kinase 1 and notch signaling pathway and uses thereof
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors
CN122031724A (zh) * 2026-04-17 2026-05-15 中国科学院杭州医学研究所 编码p16蛋白的mRNA在制备用于治疗胰腺癌的药物中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0110302A (pt) * 2000-04-18 2003-01-14 Agouron Pharma Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
US20050209297A1 (en) * 2000-08-31 2005-09-22 Pfizer Inc Pyrazole derivatives
DZ3398A1 (fr) * 2000-08-31 2002-03-07 Pfizer Prod Inc Derives pyrazole et leur utilisation comme inhibiteurs des proteines kinases
PA8850801A1 (es) * 2008-12-17 2010-07-27 Lilly Co Eli Compuestos útiles para inhibir chk1
GB201402277D0 (en) * 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
CA3013514C (en) * 2016-02-04 2021-11-23 Pharmaengine, Inc. 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications
KR20220042159A (ko) * 2019-08-01 2022-04-04 인테그랄 바이오사이언스 피브이티. 엘티디. 키나제 억제제로서의 헤테로사이클릭 화합물 및 이의 용도
CN112457306A (zh) * 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
CN111253370B (zh) 2020-03-24 2021-08-03 浙江大学 N-多取代吡啶-2-氨基嘧啶类衍生物及用途
EP4741018A3 (en) * 2020-06-19 2026-07-15 Anaxis Pharma Pty Ltd Sulphonamide compounds
BR112023002453A2 (pt) 2020-08-12 2023-05-02 Boundless Bio Inc Composições de agente de via de estresse de replicação e métodos para tratar câncer
WO2022087326A1 (en) 2020-10-23 2022-04-28 Celgene Corporation Heterocyclic compounds and their use for treatment of helminthic infections and diseases
US11564920B2 (en) 2020-11-30 2023-01-31 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1H-pyrazol-3-amine derivative
MX2023006364A (es) * 2020-11-30 2023-06-13 Sumitomo Pharma Co Ltd Derivado de 5-heteroaril-1h-pirazol-3-amina.
EP4347582A4 (en) 2021-05-27 2025-05-07 Boundless Bio, Inc. CHECKPOINT KINASE-1 INHIBITORS AND USES THEREOF
CA3241992A1 (en) 2021-12-24 2023-06-29 Seiji Kamioka 1h-pyrazole-3-amine derivative having bicyclic backbone
CN119546588A (zh) 2022-05-24 2025-02-28 无界生物公司 吡啶检查点激酶1(chk1)抑制剂及其用途
CN119255990A (zh) 2022-05-25 2025-01-03 曙方医药 作为检查点激酶1抑制剂的含氮五元杂环衍生物及其用途
JPWO2023229032A1 (cg-RX-API-DMAC7.html) 2022-05-27 2023-11-30
TW202440549A (zh) 2022-11-29 2024-10-16 美商無界生物公司 檢查點激酶1(chk1)抑制劑及其用途
EP4626433A1 (en) 2022-11-29 2025-10-08 Boundless Bio, Inc. Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof
EP4683635A1 (en) 2023-03-20 2026-01-28 Boundless Bio, Inc. Uses of a checkpoint kinase 1 (chk1) inhibitor
JP2026513823A (ja) 2023-04-03 2026-05-01 バウンドレス バイオ,インク. チェックポイントキナーゼ1(chk1)阻害剤の結晶形態およびその使用
US20260232659A1 (en) 2023-04-03 2026-08-13 Boundless Bio, Inc. Checkpoint kinase 1 (chk1) inhibitor pharmaceutical composition

Also Published As

Publication number Publication date
EP4347582A1 (en) 2024-04-10
BR112023024571A2 (pt) 2024-02-06
AU2022282384A1 (en) 2023-12-14
MX2023014028A (es) 2023-12-12
US12527790B2 (en) 2026-01-20
TW202313588A (zh) 2023-04-01
EP4347582A4 (en) 2025-05-07
IL308759A (en) 2024-01-01
CN117715905A (zh) 2024-03-15
JP2024520481A (ja) 2024-05-24
US20230026313A1 (en) 2023-01-26
CA3219348A1 (en) 2022-12-01
US11707462B2 (en) 2023-07-25
WO2022251502A1 (en) 2022-12-01
US20230310423A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
US11707462B2 (en) Checkpoint kinase 1 (CHK1) inhibitors and uses thereof
AU2023275712A1 (en) Pyridine checkpoint kinase 1 (chk1) inhibitors and uses thereof
WO2024118564A1 (en) Checkpoint kinase 1 (chk1) inhibitors and uses thereof
WO2025049814A2 (en) Ribonucleotide reductase (rnr) compositions and methods of use
TW202039489A (zh) Mat2a之雜雙環抑制劑及用於治療癌症之使用方法
CN107922431A (zh) Hpk1抑制剂及其使用方法
CA2915622A1 (en) Novel substituted bicyclic compounds as bromodomain inhibitors
WO2013170770A1 (zh) 具有抗肿瘤活性的乙炔衍生物
BR112017003312B1 (pt) Compostos de indazol como inibidores de fgfr quinase, preparação e uso dos mesmos
EP3556761B1 (en) Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof
CA3190653A1 (en) Bicyclic bromodomain inhibitors
JP2016527184A (ja) Slc2a輸送体阻害剤
WO2024118596A1 (en) Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof
KR20240101555A (ko) 사이클릭 설폰아미드 리보뉴클레오타이드 환원효소(rnr) 억제제 및 이의 용도
WO2022187200A1 (en) Ribonucleotide reductase (rnr) inhibitors and uses thereof
EP4402134A1 (en) Sulfamide ribonucleotide reductase (rnr) inhibitors and uses thereof
EA051928B1 (ru) Пиридиновые ингибиторы киназы 1 контрольной точки (chk1) и их применение
TWI423974B (zh) 三氮唑並吡啶和三氮唑並吡嗪化合物及其組合物和應用
JP2025531147A (ja) 環状スルホンアミドリボヌクレオチドレダクターゼ(rnr)阻害剤およびその使用
TW201305153A (zh) 三唑並吡啶和三唑並吡嗪化合物及其組合物和應用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231221

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250508

Comment text: Request for Examination of Application